# Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer

> **NCT02069145** · PHASE1 · COMPLETED · sponsor: **OncoMed Pharmaceuticals, Inc.** · enrollment: 10 (estimated)

## Conditions studied

- Hepatocellular Cancer
- Liver Cancer

## Interventions

- **DRUG:** OMP-54F28 with Sorafenib

## Key facts

- **NCT ID:** NCT02069145
- **Lead sponsor:** OncoMed Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2017-05
- **Final completion:** 2017-07
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2020-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02069145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02069145, "Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02069145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*